Genotypic distribution of multidrug-resistant and extensively drug-resistant tuberculosis in northern Thailand

Risara Jaksuwan¹
Prasit Tharavichikul²
Jayanton Patumanond³
Charoen Chuchottaworn⁴
Sakarin Chanwong⁵
Saijai Smithtikarn⁶
Jongkolnee Settakorn⁷

¹Clinical Epidemiology Unit,

²Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, ³Division of Clinical Epidemiology, Faculty of Medicine,

Thammasat University, Pathum Thani, ⁴Division of Respiratory Medicine, Chest Disease Institute, Nonthaburi,

⁵Office of Disease Prevention and Control Region 10, Chiang Mai, ⁶Bureau of Tuberculosis, Department of Disease Control, Ministry of Public Health, Bangkok, ⁷Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

Background: Multidrug/extensively drug-resistant tuberculosis (M/XDR-TB) is a major public health problem, and early detection is important for preventing its spread. This study aimed to demonstrate the distribution of genetic site mutation associated with drug resistance in M/XDR-TB in the northern Thai population.

Methods: Thirty-four clinical MTB isolates from M/XDR-TB patients in the upper northern region of Thailand, who had been identified for drug susceptibility using the indirect agar proportion method from 2005 to 2012, were examined for genetic site mutations of *katG*, *inhA*, and *ahpC* for isoniazid (INH) drug resistance and *rpoB* for rifampicin (RIF) drug resistance. The variables included the baseline characteristics of the resistant gene, genetic site mutations, and drug susceptibility test results.

Results: All 34 isolates resisted both INH and RIF. Thirty-two isolates (94.1%) showed a mutation of at least 1 codon for *katG*, *inhA*, and *ahpC* genes. Twenty-eight isolates (82.4%) had a mutation of at least 1 codon of *rpoB* gene. The *katG*, *inhA*, *ahpC*, and *rpoB* mutations were detected in 20 (58.7%), 27 (79.4%), 13 (38.2%), and 28 (82.3%) of 34 isolates. The 3 most common mutation codons were *katG* 315 (11/34, 35.3%), *inhA* 14 (11/34, 32.4%), and *inhA* 114 (11/34, 32.4%). For this population, the best genetic mutation test panels for INH resistance included 8 codons (*katG* 310, *katG* 340, *katG* 343, *inhA* 14, *inhA* 84, *inhA* 86, *inhA* 114, and *ahpC* 75), and for RIF resistance included 6 codons (*rpoB* 445, *rpoB* 450, *rpoB* 464, *rpoB* 490, *rpoB* 507, and *rpoB* 508) with a sensitivity of 94.1% and 82.4%, respectively.

Conclusion: The genetic mutation sites for drug resistance in M/XDR-TB are quite variable. The distribution of these mutations in a certain population must be studied before developing the specific mutation test panels for each area. The results of this study can be applied for further molecular M/XDR-TB diagnosis in the upper northern region of Thailand.

Keywords: tuberculosis, drug resistance, MDR-TB, XDR-TB, genotype, mutation

Introduction

Tuberculosis (TB) is an important global problem, especially multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). In 2015, the world-wide estimation of MDR-TB cases and deaths was 80,000 and 250,000, respectively.¹ MDR-TB is caused by *Mycobacterium tuberculosis* (MTB), which resists at least 2 drugs (isoniazid [INH] and rifampicin [RIF]). Pre-XDR-TB is a disease caused by the *M. tuberculosis* strain, which resists INH and RIF and either a fluoroquinolone or a second-line injectable drug, but not both.¹ XDR-TB is defined as MDR-TB, which adds more resistance to any fluoroquinolone and at least 1 of 3 injectable second-line drugs (amikacin, capreomycin, and kanamycin [KAN]).² Approximately 9.5% of MDR-TB

Correspondence: Jongkolnee Settakorn
Department of Pathology, Faculty of Medicine, Chiang Mai University, Inthavaroros Road, Sriphum sub-district, Mueang Chiang Mai District, Chiang Mai Province 50200, Thailand
Tel +66 53 94 5442-4
Fax +66 53 21 7144
Email jsettakorn@gmail.com

patients developed XDR-TB.¹ Unfortunately, about 20% of MDR-TB cases were undetectable.¹ Thailand is among the countries with a TB burden, as it was ranked within the top 20 countries with TB in 2015.¹

Early and accurate detection of M/XDR-TB is important for effectively treating and preventing its transmission.^{3–6} However, the phenotypic drug susceptibility test (DST) takes weeks or months for culturing MTB and identifying the resisted drugs and requires a high level of microbiological safety.^{7,8} Diagnosis and treatment delays are among the major causes of the spread of the disease, which interferes with the TB control programs. A rapid molecular TB-DST test greatly increases the efficacy of MDR-TB treatment^{5,6,9} as the minimal turnaround time is <1 day.^{10,11}

As the distribution of mutation in drug-resistant genes is region specific, knowing the epidemiology of the genetic drug resistance of M/XDR-TB in certain areas would be beneficial for developing specific and rapid molecular tests,^{8,12} as well as treatment protocols,¹³ because the prevalence of such resistance differs in various populations.^{14–16} Many studies have focused on genetic drug resistance in MTB. INH is the main drug used; it is an effective anti-TB drug and has been used till date.^{2,11} The mechanism of INH resistance in MTB is associated with the mutations of *katG*, *inhA*, and *ahpC*.^{17–19} The *katG* mutation was found in high levels of INH resistance,^{20,21} and the *inhA* mutation was found at low levels or monoresistance to INH.^{20,22} RIF is combined with INH as the main anti-TB drug, and it is inferred with transcription by the DNA-dependent RNA polymerase by binding to the β -subunit hindering transcription organisms related to *rpoB* 531 mutation,^{23–25} which destroys the organisms.^{26,27}

In this study, we examined the distribution of drug-resistant gene mutations, including *katG*, *inhA*, *ahpC*, and *rpoB*, in M/XDR-TB isolates in the northern Thai population. Then, we identified the best mutation test panels for INH and RIF resistance.

Materials and methods

Two hundred and sixty-one M/XDR-TB isolates first diagnosed with MDR-TB or XDR-TB from patients between January 2005 and June 2012 were retrieved from an archive of the Laboratory of the Office of Disease Prevention and Control Region 10 (DPC10). According to the World Health Organization (WHO) criteria, MDR isolates resisted at least INH and RIF; and XDR isolates resisted INH, RIF, ofloxacin (OFX), and KAN. DPC10 hosts a regional TB laboratory, covering 8 provinces in the north of Thailand,

and the isolates were subcultured. Only 34 specimens (9.5%) were grown in 5 mL of 7H9 broth supplemented with PANTA in 6 weeks and 3% Ogawa within 8 weeks. The bacterial agents were further examined for phenotypic DST and DNA sequencing.

Phenotypic drug susceptibility test

Thirty-four growing M/XDR-TB isolates were tested for first- and second-line drug resistance (INH, RIF, OFX, and KAN) using the proportion method with Lowensentein Jensen (LJ) medium²⁸ at DPC10 laboratory. The DOTS-plus DST was performed according to the WHO guidelines,²⁹ and all suspected TB and MDR-TB patients were investigated using 3 methods: 3 direct acid-fast bacilli sputum smear examinations, a *Mycobacterium* culture, and first-line DST,²⁹ during the first diagnosis. Additionally, at the same time, a molecular test was carried out in order to confirm *M. tuberculosis*. DST was determined using the indirect agar proportion method with INH, RIF, streptomycin, and ethambutol. If there was resistance to INH and/or RIF, a second-line anti-TB DST was performed with OFX and KAN. For our study, LJ medium was supplemented individually with anti-TB drugs. INH (0.2 μ g/mL), RIF (40.0 μ g/mL), OFX (2.0 μ g/mL), and KAN (30 μ g/mL) were repeated in order to confirm that the results were the same as the previous results; if the results were not the same then they were excluded from the study.

DNA extraction

Thirty-four M/XDR-TB isolates were cultured on solid media (LJ and OGAWA). Chromosomal DNA was extracted using the MolecuTech REBA MTB-MDR 2011 commercial kit. Briefly, 1 loop (0.2 μ L diameter sterile inoculating loop) of the cultured bacteria was resuspended in 50 μ L of DNA extraction solution. The solution was vortexed for 1 min, boiled for 10 min, and centrifuged (13,000 rpm) for 3 min at room temperature. Then, 5–10 μ L of the supernatant was transferred to a microtube (cryovial tube). The purified DNA pellet was stored at 4°C.

Sequencing method

The polymerase chain reaction (PCR) and DNA sequencing parts were carried out at MacroGen Laboratory, Seoul, Republic of Korea. Four genetic loci, *katG*, *inhA*, *ahpC* (INH), and *rpoB* (RIF), were amplified by PCR, as shown in Table S1.^{30,31} The used primers are shown in Table S1. The amplified products were purified with a multiscreen filter plate (Millipore Corp., Bedford, MA, USA).

Table 1 Frequency of genetic site mutations of *katG*, *inhA*, *ahpC*, and *rpoB* genes in 34 M/XDR-TB isolates

<i>katG</i>	n (%)	<i>inhA</i>	n (%)	<i>ahpC</i>	n (%)	<i>rpoB</i>	n (%)
<i>katG</i> 229	1 (2.9)	<i>inhA</i> 14	11 (32.4)	<i>ahpC</i> 10	4 (11.8)	<i>rpoB</i> 445	8 (23.5)
<i>katG</i> 300	1 (2.9)	<i>inhA</i> 25	1 (2.9)	<i>ahpC</i> 12	4 (11.8)	<i>rpoB</i> 450	6 (17.7)
<i>katG</i> 302	1 (2.9)	<i>inhA</i> 78	8 (23.5)	<i>ahpC</i> 20	4 (11.8)	<i>rpoB</i> 464	6 (17.7)
<i>katG</i> 308	3 (8.8)	<i>inhA</i> 81	7 (20.6)	<i>ahpC</i> 22	3 (8.8)	<i>rpoB</i> 483	4 (11.8)
<i>katG</i> 310	3 (8.8)	<i>inhA</i> 84	9 (26.5)	<i>ahpC</i> 75	7 (20.6)	<i>rpoB</i> 490	7 (20.6)
<i>katG</i> 312	4 (11.8)	<i>inhA</i> 86	8 (23.5)	<i>ahpC</i> 76	6 (17.7)	<i>rpoB</i> 493	4 (11.8)
<i>katG</i> 314	1 (2.9)	<i>inhA</i> 94	3 (8.8)			<i>rpoB</i> 507	9 (26.5)
<i>katG</i> 315	12 (35.3)	<i>inhA</i> 114	11 (32.4)			<i>rpoB</i> 508	9 (26.5)
<i>katG</i> 320	1 (2.9)						
<i>katG</i> 340	4 (11.8)						
<i>katG</i> 343	7 (20.6)						

Abbreviation: M/XDR-TB, multidrug/extensively drug-resistant tuberculosis.

Analysis

DNA sequencing analysis

The sequencing data obtained from the ABI3730XL DNA analyzer were investigated for the presence or absence of mutations by alignments with the corresponding nucleotide sequences of *M. tuberculosis* (H37RV) using the NCBI nucleotide blast program.

Data analysis

The phenotypic DST and genetic site mutation for the DST data sets were compiled using an Excel 2010 database. Statistical analysis was performed using STATA version 11.0. The resistant genes and genetic site mutations were presented according to frequency and percentage.

Results

Among the 34 growing M/XDR-TB isolates, 24 (70.5%) MDR-TB, 9 (26.5%) Pre-XDR-TB, and 1 (3.0%) XDR-TB were identified. All of the isolates were resistant to both INH and RIF. The frequency and patterns of genetic loci mutation are demonstrated in Tables 1 and 2. Table 3 exhibits the raw data of genetic mutation in all 34 isolates. Mutations were found, including *katG* in 20 isolates (58.8%), *inhA* in 27 isolates (79.4%), *ahpC* in 13 isolates (38.2%), and *rpoB* in 28 isolates (82.3%). INH-resistant gene mutations were found in 32 isolates (94.1% sensitivity). RIF-resistant gene mutations were identified in 28 isolates (82.4% sensitivity).

One isolate revealed no mutation for the studied genetic loci (no. 18). Two isolates showed no mutation for *katG*, *inhA*, or *ahpC*. (no. 2 and 18). For the INH-resistant genes, a single-gene mutation was found in 10 isolates (29.4%), 2 for *katG*, 7 for *inhA*, and 1 for *ahpC*. Double mutation was found in 16 isolates (47.1%), 10 for *katG/inhA*, 4 for *inhA/ahpC*, and 2 for *katG/ahpC*. Triple *katG/inhA/ahpC* mutation was seen in 6 isolates (17.6%). Regarding the RIF-resistant

Table 2 Distribution of *Mycobacterium tuberculosis* genetic mutations with isoniazid and rifampicin resistance

Gene mutation codon	n	%
<i>katG</i>		
No mutation	14	41.3
<i>katG</i> 315	9	26.7
<i>katG</i> 320	1	2.9
<i>katG</i> 312	1	2.9
<i>katG</i> 343	1	2.9
<i>katG</i> 315 and <i>katG</i> 343	1	2.9
<i>katG</i> 308 and <i>katG</i> 310	1	2.9
<i>katG</i> 312 and <i>katG</i> 343	2	5.9
<i>katG</i> 308, <i>katG</i> 315, and <i>katG</i> 340	1	2.9
<i>katG</i> 315, <i>katG</i> 340, and <i>katG</i> 343	1	2.9
<i>katG</i> 310, <i>katG</i> 314, <i>katG</i> 340, and <i>katG</i> 343	1	2.9
<i>katG</i> 299, <i>katG</i> 300, <i>katG</i> 302, <i>katG</i> 310, and <i>katG</i> 312	1	2.9
<i>inhA</i>		
No mutation	7	20.6
<i>inhA</i> 14	6	17.7
<i>inhA</i> 25	1	2.9
<i>inhA</i> 86	1	2.9
<i>inhA</i> 114	5	14.8
<i>inhA</i> 14 and <i>inhA</i> 114	4	11.8
<i>inhA</i> 84 and <i>inhA</i> 114	1	2.9
<i>inhA</i> 78, <i>inhA</i> 81, and <i>inhA</i> 84	1	2.9
<i>inhA</i> 78, <i>inhA</i> 81, and <i>inhA</i> 86	1	2.9
<i>inhA</i> 78, <i>inhA</i> 84, and <i>inhA</i> 86	1	2.9
<i>inhA</i> 14, <i>inhA</i> 78, <i>inhA</i> 81, and <i>inhA</i> 84	1	2.9
<i>inhA</i> 78, <i>inhA</i> 81, <i>inhA</i> 84, and <i>inhA</i> 86	1	2.9
<i>inhA</i> 78, <i>inhA</i> 84, <i>inhA</i> 86, and <i>inhA</i> 114	1	2.9
<i>inhA</i> 81, <i>inhA</i> 84, <i>inhA</i> 86, and <i>inhA</i> 94	1	2.9
<i>inhA</i> 78, <i>inhA</i> 81, <i>inhA</i> 84, <i>inhA</i> 86, and <i>inhA</i> 94	2	5.9
<i>ahpC</i>		
No mutation	21	61.8
<i>ahpC</i> 10	1	2.9
<i>ahpC</i> 75	1	2.9
<i>ahpC</i> 10 and <i>ahpC</i> 12	1	2.9
<i>ahpC</i> 12 and <i>ahpC</i> 20	1	2.9
<i>ahpC</i> 75 and <i>ahpC</i> 76	6	17.7
<i>ahpC</i> 10, <i>ahpC</i> 20, and <i>ahpC</i> 22	1	2.9
<i>ahpC</i> 12, <i>ahpC</i> 20, and <i>ahpC</i> 22	1	2.9
<i>ahpC</i> 10, <i>ahpC</i> 12, <i>ahpC</i> 20, and <i>ahpC</i> 22	1	2.9

(Continued)

Table 2 (Continued)

Gene mutation codon	n	%
<i>rpoB</i>		
No mutation	6	17.7
<i>rpoB</i> 445	2	5.9
<i>rpoB</i> 508	1	2.9
<i>rpoB</i> 464	2	5.9
<i>rpoB</i> 450	3	8.8
<i>rpoB</i> 490	2	5.9
<i>rpoB</i> 507	3	8.8
<i>rpoB</i> 445 and <i>rpoB</i> 508	1	2.9
<i>rpoB</i> 507 and <i>rpoB</i> 508	6	17.7
<i>rpoB</i> 445 and <i>rpoB</i> 483	1	2.9
<i>rpoB</i> 464 and <i>rpoB</i> 483	1	2.9
<i>rpoB</i> 445, <i>rpoB</i> 464, and <i>rpoB</i> 504	1	2.9
<i>rpoB</i> 445, <i>rpoB</i> 490, and <i>rpoB</i> 493	1	2.9
<i>rpoB</i> 450, <i>rpoB</i> 490, and <i>rpoB</i> 493	1	2.9
<i>rpoB</i> 445, <i>rpoB</i> 464, <i>rpoB</i> 490, and <i>rpoB</i> 493	1	2.9
<i>rpoB</i> 450, <i>rpoB</i> 490, <i>rpoB</i> 483, and <i>rpoB</i> 493	1	2.9
<i>rpoB</i> 445, <i>rpoB</i> 464, <i>rpoB</i> 490, <i>rpoB</i> 483, and <i>rpoB</i> 493	1	2.9

gene, no *rpoB* mutation was found in 6 isolates (no. 5, 8, 11, 15, 8, and 34).

The common mutated genetic loci found in M/XDR-TB were *katG* 315 (n=12, 35.3%), *inhA* 14 (n=11, 32.4%), *ihnA* 114 (n=11, 32.4%), *ihnA* 84 (n=9, 26.5%), *rpoB* 507 (n=9, 26.47%), and *rpoB* 508 (n=9, 26.47%).

Discussion

The frequency and distribution of drug-resistant mutations are variable across regions and countries (Table 4). The frequency of *katG* mutation ranged from 58.5% to 93.7%,³⁹ and the most commonly mutated *katG* locus was *katG* 315.^{32–37,39,40} The reported frequency of *inhA* mutation was 4.7%–79.4%,^{32,33} and the most commonly mutated *inhA* locus was *inhA* 15.^{32–40} The frequency of *ahpC* mutation was relatively low (9.1%–38.2%)^{34,35} and was extremely

Table 3 Raw distribution of genetic site mutations of *katG*, *inhA*, *ahpC*, and *rpoB* genes in M/XDR-TB isolates

No.	<i>katG</i> 299	<i>katG</i> 300	<i>katG</i> 302	<i>katG</i> 308	<i>katG</i> 310	<i>katG</i> 312	<i>katG</i> 314	<i>katG</i> 315	<i>katG</i> 320	<i>katG</i> 340	<i>katG</i> 343	<i>inhA</i> 14	<i>inhA</i> 25	<i>inhA</i> 78	<i>inhA</i> 81	<i>inhA</i> 84
1	Y	Y	Y	Y	Y	Y	-	-	-	-	-	-	-	-	-	-
2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3	-	-	-	-	-	-	-	-	-	-	Y	-	Y	-	-	-
4	-	-	-	-	-	Y	-	-	-	-	Y	-	-	-	-	Y
5	-	-	-	Y	Y	-	-	-	-	-	-	-	-	-	-	-
6	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-
7	-	-	-	-	-	-	-	Y	-	Y	Y	Y	-	-	-	-
8	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	-
9	-	-	-	-	-	-	-	Y	-	-	Y	Y	-	-	-	-
10	-	-	-	-	-	Y	-	-	-	-	Y	-	-	Y	Y	Y
11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	-	-	-	Y	-	-	-	Y	-	Y	-	Y	-	-	-	-
13	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-
15	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	-
16	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
17	-	-	-	-	-	Y	-	-	-	Y	Y	-	-	Y	-	Y
18	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
19	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	-
20	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	Y
21	-	-	-	-	-	-	-	-	-	-	-	Y	-	Y	Y	Y
22	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-
23	-	-	-	-	Y	-	Y	-	-	Y	Y	-	-	Y	Y	Y
24	-	-	-	-	-	-	-	Y	-	-	-	-	-	Y	Y	-
25	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-
26	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	-
27	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	-
28	-	-	-	-	-	-	-	Y	-	-	-	-	-	Y	Y	Y
29	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	Y
30	-	-	-	-	-	-	-	-	Y	-	-	-	-	-	Y	Y
31	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-
32	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-
33	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-

Notes: -, no mutation; Y, presence of mutation; gray column, proposed mutation test panels.

Abbreviation: M/XDR-TB, multidrug/extensively drug-resistant tuberculosis.

variable. The frequency of *rpoB* mutation was relatively high (80.8%–97.0%),^{33,34,39} predominantly at the locus *rpoB* 531.

Genomic tests or multiple genetic loci tests are not suitable for resource-limited countries. Developing test panels for M/XDR-TB drug-resistant genes would be more cost-effective if the test panels of the selected genetic loci provide high sensitivity and specificity. However, as the distributions of the gene mutations across the regions varied, a deeper analysis should be considered in further studies. The distribution of mutation patterns should be examined in each geographical areas before routine diagnostic services being implemented. According to the results of this study, we selected 8 INH-resistant gene mutation loci (*katG* 310, *katG* 340, *katG* 343, *inhA* 14, *inhA* 84, *inhA* 86, *inhA* 114, and *ahpC* 75) and 6 RIF-resistant gene mutation loci (*rpoB* 445, *rpoB* 450, *rpoB* 464, *rpoB* 490, *rpoB* 507, and *rpoB* 508) as the best panels for genetic

drug resistance tests. Both the panels were able to detect all isolates with at least 1 mutation site for any *katG/inhA/ahpC* mutation and *rpoB* mutation. The sensitivities of the proposed INH resistance mutation test was 94.1% (32/34), while that of the RIF resistance mutation test was 82.4% (28/34).

Limitations

The limitations of this study were the small sample size and the retrospective design. Only 34 isolates were available from a total of 261 isolates. Another weak point was that there was no control group, such as non-M/XDR-TB isolates.

Conclusion

The results of this study confirm the presence of genetic drug-resistant mutations in the M/XDR-TB isolates in upper northern Thailand. We showed that our mutation patterns

<i>inhA</i> 86	<i>inhA</i> 94	<i>inhA</i> 114	<i>ahpC</i> 10	<i>ahpC</i> 12	<i>ahpC</i> 20	<i>ahpC</i> 22	<i>ahpC</i> 75	<i>ahpC</i> 76	<i>rpoB</i> 445	<i>rpoB</i> 450	<i>rpoB</i> 464	<i>rpoB</i> 483	<i>rpoB</i> 490	<i>rpoB</i> 493	<i>rpoB</i> 507	<i>rpoB</i> 508
-	-	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	Y
-	-	-	-	-	-	-	-	-	Y	-	Y	-	-	-	-	Y
-	-	-	Y	-	-	-	-	-	-	-	-	-	Y	-	-	-
-	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y
-	-	Y	-	-	-	-	-	-	Y	-	-	Y	-	-	-	-
-	-	Y	-	Y	Y	Y	-	-	Y	-	Y	Y	Y	Y	-	-
-	-	Y	Y	Y	Y	Y	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	Y	-	-	Y	Y	-	-
Y	-	-	-	-	-	-	-	-	Y	-	-	-	Y	Y	-	-
-	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-
-	-	-	Y	-	Y	Y	-	-	-	-	-	-	-	-	Y	Y
-	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
-	-	Y	Y	Y	-	-	-	Y	Y	-	-	-	-	-	-	-
-	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-
Y	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-
Y	-	Y	-	-	-	-	-	-	-	Y	-	Y	Y	Y	-	-
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	Y	-	-	-	-	-	-
Y	-	-	-	-	-	-	Y	-	Y	Y	Y	-	Y	-	-	-
-	-	Y	-	-	-	-	-	-	Y	-	-	-	-	-	-	-
Y	Y	-	-	Y	Y	-	-	-	-	Y	-	-	-	-	-	-
Y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y
-	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y
Y	Y	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y
-	-	-	-	-	-	-	-	-	-	-	Y	Y	-	-	-	-
Y	Y	-	-	-	-	-	-	-	-	-	Y	-	-	-	-	-
-	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	-	-	-
-	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-	Y	-
-	-	Y	-	-	-	-	Y	Y	-	-	-	-	-	-	Y	-
-	-	Y	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-

Table 4 Distribution of genetic mutation for isoniazid and rifampicin resistance

Countries	<i>katG</i> (n %), top 3 common loci	<i>inhA</i> (n %), top 3 common loci	<i>ahpC</i> (n %), top 3 common loci	<i>rpoB</i> (n %), top 3 common loci
Thailand (the present study) in the north of Thailand	20/34 (58.8%) 315, 343, 312, 340	27/34 (79.4%) 14, 114, 84	13/34 (38.2%) 75, 76, 10, 12, 20	28/34 (82.3%) 507, 508, 445
Thailand ³² (in the middle of Thailand in 2007)	25/29 (86.21%) 315, 463, 308	7/25 (24.0%) (-15), (-8), 21	NA	NA
Myanmar ³³	31/33 (72.1%) 315	2/33 (4.7%) (-15)	NA	32/33 (97.0%) 531, 526, 516
People's Republic of China ³⁴	178/242 (73.9%) 315, 295, 299	26/242 (10.7%) (15), (-8), 25	22/242 (9.1%) (-10), (-6), (-12)	213/242 (88.0%) 531, 526, 516
Poland ³⁵	40/50 (80%) 315, 463, 234	8/50 (16%) (-15), (-8), 289	5/50 (10%) 48, 54, 57	NA
Switzerland ³⁶	101/154 (65.6%) 315	35/154 (22.7%) (-15)	NA	NA
Argentina ³⁷	43/71 (60.5%) 315	16/71 (22.5%) (-15)	NA	NA
South Africa ³⁸	NA	165/232 (71%) (-15), (-8)	NA	NA
Morocco ³⁹	15/16 (93.7%) 315	1/16 (6.2%) (-15)	NA	21/26 (80.8%) 531, 316, 513, 526
India, Moldova, Philippines, and South Africa ⁴⁰	268/316 (84.8%) 315	101/316 (32.0%) (-15), (-8), (-17)	NA	NA

Abbreviation: NA, not available.

were different from other parts of Thailand and other countries. The distribution of these mutations in certain populations must be studied before developing specific mutation test panels for each area. These data and proposed mutation panels can be applied for further molecular M/XDR-TB diagnosis in the upper northern region of Thailand.

Acknowledgments

We would like to thank all the staff members in DPC10 as well as Nakornping Hospital, Chiang Rai Hospital, Lampang Hospital, Phayao Hospital, Chiang Kam Hospital, Lamphun Hospital, Phrae Hospital, and Nan Hospital for their cooperation. This study was supported by the National Research Council of Thailand and the Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. The study was also partly supported by the Thailand National Research University (NRU) Fund.

Author contributions

All authors contributed toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.

Disclosure

All the authors report no conflicts of interest in this work.

References

- World Health Organization. Global tuberculosis report 2016. WHO/HTM/TB/2016.13 ed. France: World Health Organization; 2016.
- World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, Switzerland: WHO Document Production Services; 2014.
- Ahmad S, Mokaddas E. Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis. *J Infect Public Health*. 2014;7(2):75–91.
- Liang L, Wu Q, Gao L, et al. Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China. *Thorax*. 2012; 67(7):632–638.
- Lange C, Abubakar I, Alffenaar JW, et al; TBNET. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. *Eur Respir J*. 2014;44(1): 23–63.
- Porwal C, Kaushik A, Makkar N, et al. Incidence and risk factors for extensively drug-resistant tuberculosis in Delhi region. *PLoS One*. 2013; 8(2):e55299.
- Paramasivan CN, Lee E, Kao K, et al. Experience establishing tuberculosis laboratory capacity in a developing country setting. *Int J Tuberc Lung Dis*. 2010;14(1):59–64.
- Parsons LM, Somoskövi A, Gutierrez C, et al. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. *Clin Microbiol Rev*. 2011;24(2):314–350.
- Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. *N Engl J Med*. 2010;363(11): 1005–1015.
- World Health Organization. *Guidelines for the programmatic management of drug-resistant tuberculosis – 2011 update*. Version March 2010. Available from: http://apps.who.int/iris/bitstream/10665/44597/1/9789241501583_eng.pdf. Accessed May 17, 2017.
- Heysell SK, Hout ER. The future of molecular diagnostics for drug-resistant tuberculosis. *Expert Rev Mol Diagn*. 2012;12(4):395–405.
- Lin SY, Desmond EP. Molecular diagnosis of tuberculosis and drug resistance. *Clin Lab Med*. 2014;34(2):297–314.
- Chan RC, Hui M, Chan EW, et al. Genetic and phenotypic characterization of drug-resistant *Mycobacterium tuberculosis* isolates in Hong Kong. *J Antimicrob Chemother*. 2007;59(5):866–873.
- Hofmann-Thiel S, van Ingen J, Feldmann K, et al. Mechanisms of heteroresistance to isoniazid and rifampin of *Mycobacterium tuberculosis* in Tashkent, Uzbekistan. *Eur Respir J*. 2009;33(2):368–374.

15. Ilina EN, Shitikov EA, Ikryannikova LN, et al. Comparative genomic analysis of *Mycobacterium tuberculosis* drug resistant strains from Russia. *PLoS One*. 2013;8(2):e56577.
16. Lopez-Alvarez R, Badillo-Lopez C, Cerna-Cortes JF, et al. First insights into the genetic diversity of *Mycobacterium tuberculosis* isolates from HIV-infected Mexican patients and mutations causing multidrug resistance. *BMC Microbiol*. 2010;10:82.
17. Sherman DR, Mdluli K, Hickey MJ, et al. Compensatory *ahpC* gene expression in isoniazid-resistant *Mycobacterium tuberculosis*. *Science*. 1996;272(5268):1641–1643.
18. Almeida Da Silva PE, Palomino JC. Molecular basis and mechanisms of drug resistance in *Mycobacterium tuberculosis*: classical and new drugs. *J Antimicrob Chemother*. 2011;66(7):1417–1430.
19. Seifert M, Catanzaro D, Catanzaro A, Rodwell TC. Genetic mutations associated with isoniazid resistance in *Mycobacterium tuberculosis*: a systematic review. *PLoS One*. 2015;10(3):e0119628.
20. Miyata M, Pavan FR, Sato DN, et al. Drug resistance in *Mycobacterium tuberculosis* clinical isolates from Brazil: phenotypic and genotypic methods. *Biomed Pharmacother*. 2011;65(6):456–459.
21. Ameeruddin NU, Luke Elizabeth H. Impact of isoniazid resistance on virulence of global and south Indian clinical isolates of *Mycobacterium tuberculosis*. *Tuberculosis (Edinb)*. 2014;94(6):557–563.
22. Banerjee A, Dubnau E, Quemard A, et al. *inhA*, a gene encoding a target for isoniazid and ethionamide in *Mycobacterium tuberculosis*. *Science*. 1994;263(5144):227–230.
23. Li QJ, Jiao WW, Yin QQ, et al. Compensatory mutations of rifampin resistance are associated with transmission of multidrug-resistant *Mycobacterium tuberculosis* Beijing genotype strains in China. *Antimicrob Agents Chemother*. 2016;60(5):2807–2812.
24. Meftahi N, Namouchi A, Mhenni B, Brandis G, Hughes D, Mardassi H. Evidence for the critical role of a secondary site *rpoB* mutation in the compensatory evolution and successful transmission of an MDR tuberculosis outbreak strain. *J Antimicrob Chemother*. 2016;71(2):324–332.
25. Pavankumar AR, Engström A, Liu J, Herthnek D, Nilsson M. Proficient detection of multi-drug-resistant *Mycobacterium tuberculosis* by padlock probes and lateral flow nucleic acid biosensors. *Anal Chem*. 2016;88(8):4277–4284.
26. Herrera L, Jiménez S, Valverde A, García-Aranda MA, Sáez-Nieto JA. Molecular analysis of rifampicin-resistant *Mycobacterium tuberculosis* isolated in Spain (1996–2001). Description of new mutations in the *rpoB* gene and review of the literature. *Int J Antimicrob Agents*. 2003;21(5):403–408.
27. Palomino JC, Martin A. Drug resistance mechanisms in *Mycobacterium tuberculosis*. *Antibiotics*. 2014;3(3):317–340.
28. World Health Organization. Guidelines for drug susceptibility testing for second-line anti-tuberculosis drugs for DOTS-plus 2001. Geneva: World Health Organization; 2001. Available from www.WHO_CDS_TB_2001.288_eng.pdf. Accessed May 8, 2017.
29. Department of Disease Control, Ministry of Public Health, Bangkok, Thailand. [The Thailand's 2008 National MDR-TB Management Guidelines. Bangkok, Thailand]: The Bureau of Tuberculosis of Thailand; 2001. Thai.
30. Afanas'ev MV, Ikryannikova LN, Il'ina EN, et al. Molecular characteristics of rifampicin- and isoniazid-resistant *Mycobacterium tuberculosis* isolates from the Russian Federation. *J Antimicrob Chemother*. 2007;59(6):1057–1064.
31. Valvatne H, Syre H, Kross M, et al. Isoniazid and rifampicin resistance-associated mutations in *Mycobacterium tuberculosis* isolates from Yangon, Myanmar: implications for rapid molecular testing. *J Antimicrob Chemother*. 2009;64(4):694–701.
32. Khadka DK, Eampokalap B, Panitchakorn J, Ramasoota P, Khusmith S. Multiple mutations in *katG* and *inhA* identified in Thai isoniazid-resistant *Mycobacterium tuberculosis* isolates. *Southeast Asian J Trop Med Public Health*. 2007;38(2):376–382.
33. Aung WW, Ei PW, Nyunt WW, et al. Phenotypic and genotypic analysis of anti-tuberculosis drug resistance in *Mycobacterium tuberculosis* isolates in Myanmar. *Ann Lab Med*. 2015;35(5):494–499.
34. Luo T, Zhao M, Li X, et al. Selection of mutations to detect multidrug-resistant *Mycobacterium tuberculosis* strains in Shanghai, China. *Antimicrob Agents Chemother*. 2010;54(3):1075–1081.
35. Jagielski T, Bakula Z, Roeske K, et al. Detection of mutations associated with isoniazid resistance in multidrug-resistant *Mycobacterium tuberculosis* clinical isolates. *J Antimicrob Chemother*. 2014;69(9):2369–2375.
36. Fenner L, Egger M, Bodmer T, et al; Swiss HIV Cohort Study and the Swiss Molecular Epidemiology of Tuberculosis Study Group. Effect of mutation and genetic background on drug resistance in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother*. 2012;56(6):3047–3053.
37. Imperiale BR, Zumárraga MJ, Di Giulio AB, Cataldi AA, Morcillo NS. Molecular and phenotypic characterisation of *Mycobacterium tuberculosis* resistant to anti-tuberculosis drugs. *Int J Tuberc Lung Dis*. 2013;17(8):1088–1093.
38. Niehaus AJ, Mlisana K, Gandhi NR, Mathema B, Brust JC. High prevalence of *inhA* promoter mutations among patients with drug-resistant tuberculosis in KwaZulu-Natal, South Africa. *PLoS One*. 2015;10(9):e0135003.
39. Zakham F, Chaoui I, Echchaoui AH, et al. Direct sequencing for rapid detection of multidrug resistant *Mycobacterium tuberculosis* strains in Morocco. *Infect Drug Resist*. 2013;6:207–213.
40. Torres JN, Paul LX, Rodwell TC, et al. Novel *katG* mutations causing isoniazid resistance in clinical *M. tuberculosis* isolates. *Emerg Microbes Infect*. 2015;4(7):e42.

Supplementary material

Table S1 Primers used for sequencing

Gene	Primer	Nucleotide sequencing (5'–3')	Product size (pb)	Temperature (°C)	Reference
<i>katG</i>	MtkatGf	ACCCGAGGCTGCTCCGCTGG	168	94°C – 20 s 50°C – 20 s 70 cycles 72°C – 20 s	Afanas'ev ¹
<i>inhA</i>	MtkatGr MtfabGf	CAGCTCCCACTCGTAGCCGT GCCTCGCTGGCCAGAAAGG	320	94°C – 20 s 56°C – 20 s 70 cycles 72°C – 20 s	Afanas'ev ¹
<i>ahpC</i>	MtfabGr ahpCI F	CTCCGGATCCACGGTGGGT GCCTGGGTGTTCTCACTGGT	359	95°C – 40 s 15 min (start) 94°C – 40 s 30 cycles 57°C – 40 s 1 min 72°C – 40 s 15 min (final)	Valvatne ²
<i>rpoB</i>	ahpC2 R MtrpoBf	CGCAACGTCGACTGGCTCATA GAGGCGATCACCGCAGAC	321	94°C – 20 s 59°C – 20 s 70 cycles 72°C – 20 s	Afanas'ev ¹
	MtrpoBr	GGTACGGCGTTTCGATGAAC			

References

1. Afanas'ev MV, Ikryannikova LN, Il'ina EN, et al. Molecular characteristics of rifampicin- and isoniazid-resistant *Mycobacterium tuberculosis* isolates from the Russian Federation. *J Antimicrob Chemother.* 2007;59(6):1057–1064.
2. Valvatne H, Syre H, Kross M, et al. Isoniazid and rifampicin resistance-associated mutations in *Mycobacterium tuberculosis* isolates from Yangon, Myanmar: implications for rapid molecular testing. *J Antimicrob Chemother.* 2009;64(4):694–701.

Infection and Drug Resistance

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of antibiotic

resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>

Dovepress